Lepu Medical Tech Beijing vs Zhonghong Pulin Medical Products: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Lepu Medical Tech Beijing (300003.CS)

Q3 202615 Jul – 8 Oct 2026

▲3▼1

Lepu's profit slump meets a wave of obesity-drug trial wins

Profit and sales fell as procurement squeezed prices First-half 2026 revenue slipped 4.6% and net profit dropped about 28% from a year earlier, with the second quarter also weaker. Management blames government bulk-buying (procurement) that forces down prices on its medical consumables and generic drugs. Falling profit and margins weigh on the share price.
The core earnings deterioration is the main drag on the stock and the backdrop for everything else.
Obesity and muscle-preserving drug pipeline advances Two experimental obesity shots from subsidiary Shanghai Minwei won Chinese clinical trial approval: MWN110, an antibody that cuts fat while preserving muscle, and MWN117, a longer-acting treatment. Neither has any approved rival worldwide yet. This optional new growth story supports the share price even though sales are years away.
The pipeline is the main positive force offsetting the weak core business.
US FDA clears both obesity drugs for trials The US drug regulator agreed to let Lepu test MWN110 and MWN117 in clinical trials, opening a path to the huge American market. Both already had Chinese approval. This global validation raises the pipeline's potential value, though trials are early and could still fail.
US clearance is a fresh, concrete step that lifts the value of the pipeline story.
Dividend and chairman buying signal confidence Lepu will pay a cash dividend of about 1.63 yuan per 10 shares, roughly 300 million yuan total, and the chairman bought more shares at about 11.71 yuan, promising not to sell for six months. These moves put cash in shareholders' hands and show insider belief in the company's value.
Payout and insider buying are tangible supports for investor sentiment amid the profit decline.

August 202615 Jul – 8 Oct 2026

▲3▼1

Lepu's profit slump meets a wave of obesity-drug trial wins

Profit and sales fell as procurement squeezed prices First-half 2026 revenue slipped 4.6% and net profit dropped about 28% from a year earlier, with the second quarter also weaker. Management blames government bulk-buying (procurement) that forces down prices on its medical consumables and generic drugs. Falling profit and margins weigh on the share price.
The core earnings deterioration is the main drag on the stock and the backdrop for everything else.
Obesity and muscle-preserving drug pipeline advances Two experimental obesity shots from subsidiary Shanghai Minwei won Chinese clinical trial approval: MWN110, an antibody that cuts fat while preserving muscle, and MWN117, a longer-acting treatment. Neither has any approved rival worldwide yet. This optional new growth story supports the share price even though sales are years away.
The pipeline is the main positive force offsetting the weak core business.
US FDA clears both obesity drugs for trials The US drug regulator agreed to let Lepu test MWN110 and MWN117 in clinical trials, opening a path to the huge American market. Both already had Chinese approval. This global validation raises the pipeline's potential value, though trials are early and could still fail.
US clearance is a fresh, concrete step that lifts the value of the pipeline story.
Dividend and chairman buying signal confidence Lepu will pay a cash dividend of about 1.63 yuan per 10 shares, roughly 300 million yuan total, and the chairman bought more shares at about 11.71 yuan, promising not to sell for six months. These moves put cash in shareholders' hands and show insider belief in the company's value.
Payout and insider buying are tangible supports for investor sentiment amid the profit decline.

Latest15 Jul – 8 Oct 2026

▲3▼1

Lepu's profit slump meets a wave of obesity-drug trial wins

Profit and sales fell as procurement squeezed prices First-half 2026 revenue slipped 4.6% and net profit dropped about 28% from a year earlier, with the second quarter also weaker. Management blames government bulk-buying (procurement) that forces down prices on its medical consumables and generic drugs. Falling profit and margins weigh on the share price.
The core earnings deterioration is the main drag on the stock and the backdrop for everything else.
Obesity and muscle-preserving drug pipeline advances Two experimental obesity shots from subsidiary Shanghai Minwei won Chinese clinical trial approval: MWN110, an antibody that cuts fat while preserving muscle, and MWN117, a longer-acting treatment. Neither has any approved rival worldwide yet. This optional new growth story supports the share price even though sales are years away.
The pipeline is the main positive force offsetting the weak core business.
US FDA clears both obesity drugs for trials The US drug regulator agreed to let Lepu test MWN110 and MWN117 in clinical trials, opening a path to the huge American market. Both already had Chinese approval. This global validation raises the pipeline's potential value, though trials are early and could still fail.
US clearance is a fresh, concrete step that lifts the value of the pipeline story.
Dividend and chairman buying signal confidence Lepu will pay a cash dividend of about 1.63 yuan per 10 shares, roughly 300 million yuan total, and the chairman bought more shares at about 11.71 yuan, promising not to sell for six months. These moves put cash in shareholders' hands and show insider belief in the company's value.
Payout and insider buying are tangible supports for investor sentiment amid the profit decline.

Zhonghong Pulin Medical Products Co. Ltd. (300981.CS)

Q3 202628 Jul – 26 Aug 2026

▲3▼1

Glove Price Surge Drives Zhonghong Medical Profit Explosion

First-Half Profit Forecast Surges Over 23-Fold Zhonghong Medical expects first-half 2026 net profit of 140–210 million yuan, up 2,338%–3,557% year-on-year, driven by higher selling prices for health protection gloves and improved cost control. This signals a strong turnaround and boosts investor confidence, pushing the stock price up.
This is the core new event that directly explains the profit surge and its cause.
Actual First-Half Net Profit Jumps 26-Fold The semi-annual report confirmed net profit of 159 million yuan, up 2,662% year-on-year, with second-quarter profit alone at 154 million yuan. Revenue rose 19.46% to 1.478 billion yuan. This concrete result validates the earlier forecast and reinforces the positive price trend.
It provides the actual financial outcome, confirming the earlier forecast and strengthening the investment case.
Stock Price Rises Over 50% Since July As of August 25, the share price stood at 14.77 yuan, up more than 50% since July, with a market value of 6.3 billion yuan. This reflects the market's positive reaction to the profit surge and improving fundamentals.
It shows the market's cumulative response to the profit news, indicating sustained upward momentum.
Large Foreign Exchange Loss from Yuan-Dollar Swings The company incurred a large exchange loss due to fluctuations in the yuan against the US dollar. Excluding this, operating performance would have been even stronger. This is a real counterweight that partially offsets the profit surge and could pressure future earnings if currency volatility continues.
It presents a genuine risk factor that tempers the positive profit news and could affect future profitability.

August 202628 Jul – 26 Aug 2026

▲3▼1

Glove Price Surge Drives Zhonghong Medical Profit Explosion

First-Half Profit Forecast Surges Over 23-Fold Zhonghong Medical expects first-half 2026 net profit of 140–210 million yuan, up 2,338%–3,557% year-on-year, driven by higher selling prices for health protection gloves and improved cost control. This signals a strong turnaround and boosts investor confidence, pushing the stock price up.
This is the core new event that directly explains the profit surge and its cause.
Actual First-Half Net Profit Jumps 26-Fold The semi-annual report confirmed net profit of 159 million yuan, up 2,662% year-on-year, with second-quarter profit alone at 154 million yuan. Revenue rose 19.46% to 1.478 billion yuan. This concrete result validates the earlier forecast and reinforces the positive price trend.
It provides the actual financial outcome, confirming the earlier forecast and strengthening the investment case.
Stock Price Rises Over 50% Since July As of August 25, the share price stood at 14.77 yuan, up more than 50% since July, with a market value of 6.3 billion yuan. This reflects the market's positive reaction to the profit surge and improving fundamentals.
It shows the market's cumulative response to the profit news, indicating sustained upward momentum.
Large Foreign Exchange Loss from Yuan-Dollar Swings The company incurred a large exchange loss due to fluctuations in the yuan against the US dollar. Excluding this, operating performance would have been even stronger. This is a real counterweight that partially offsets the profit surge and could pressure future earnings if currency volatility continues.
It presents a genuine risk factor that tempers the positive profit news and could affect future profitability.

Latest28 Jul – 26 Aug 2026

▲3▼1

Glove Price Surge Drives Zhonghong Medical Profit Explosion

First-Half Profit Forecast Surges Over 23-Fold Zhonghong Medical expects first-half 2026 net profit of 140–210 million yuan, up 2,338%–3,557% year-on-year, driven by higher selling prices for health protection gloves and improved cost control. This signals a strong turnaround and boosts investor confidence, pushing the stock price up.
This is the core new event that directly explains the profit surge and its cause.
Actual First-Half Net Profit Jumps 26-Fold The semi-annual report confirmed net profit of 159 million yuan, up 2,662% year-on-year, with second-quarter profit alone at 154 million yuan. Revenue rose 19.46% to 1.478 billion yuan. This concrete result validates the earlier forecast and reinforces the positive price trend.
It provides the actual financial outcome, confirming the earlier forecast and strengthening the investment case.
Stock Price Rises Over 50% Since July As of August 25, the share price stood at 14.77 yuan, up more than 50% since July, with a market value of 6.3 billion yuan. This reflects the market's positive reaction to the profit surge and improving fundamentals.
It shows the market's cumulative response to the profit news, indicating sustained upward momentum.
Large Foreign Exchange Loss from Yuan-Dollar Swings The company incurred a large exchange loss due to fluctuations in the yuan against the US dollar. Excluding this, operating performance would have been even stronger. This is a real counterweight that partially offsets the profit surge and could pressure future earnings if currency volatility continues.
It presents a genuine risk factor that tempers the positive profit news and could affect future profitability.